Ultragenyx Pharmaceutical Inc. (RARE) Earnings Call Transcript
November 4, 2025
Earnings Call Speaker Segments
Thanks. A press release has been put out that breaks down our financial results, and it's available on our website, ultragenyx.com. On this call with me are Emil Kakkis, our Chief Executive Officer and President, Erik Harris, our Chief Commercial Officer, Howard Horn, our Chief Financial Officer, and Eric Crombez, our Chief Medical Officer. Everyone should be aware that forward-looking statements will be made during today's call. Certain risks and uncertainties apply to those statements, and our actual results may differ materially. Please look at the risk factors covered in our latest SEC filings. Emil, I'll hand the call over to you now.
Appreciate that, Josh, and good afternoon to all of you. Ultragenyx today stands right at the edge of major transformation and expansion; four products are already on the market, and those have consistently produced substantial double-digit yearly revenue increases across many years. Two BLA filings are currently underway for programs designed to tackle serious medical needs affecting patients who suffer from ultra-rare diseases; beyond that, we have several late-stage clinical efforts carrying breakthrough commercial promise that are nearing pivotal readouts. This is a pivotal juncture for our company, and I'm happy to say our team stands prepared to seize the opportunities in front of us. Earlier today we shared that we've taken a meaningful step toward reinforcing our financial standing, securing $400 million in non-dilutive capital from OMERS via the cap sale of a share of our Crysvita royalties. Crucially, we managed to push back when payments begin under this arrangement until January 2028. This capital, along with that schedule, reinforces our balance sheet as we get closer to pivotal data readouts for our biggest commercial opportunities in osteogenesis imperfecta and Angelman syndrome. Crucially, we will keep concentrating on controlling our cash burn and making our investments a priority. Moving to the clinical side, we keep witnessing thrilling momentum throughout our late-stage programs, starting with GTX-102, our investigational antisense oligonucleotide aimed at Angelman syndrome; back in July, we reported that the pivotal 48-week Aspire study had finished enrolling with 129 patients, and data from it should be available in the second half of 2026. Last week, we reported that the first patient had received a dose in the phase II/III Aurora study, which assesses GTX-102 across additional ages and genotypes. That trial, together with the completely enrolled phase III Aspire study, will produce data spanning the full range of genotypes and ages. Moving on to UX143 for treating osteogenesis imperfecta, execution of the phase III Orbit and Cosmic study keeps going smoothly. Investigators with patients in the open-label phase II tell us stories about how well those patients are doing, the gains in their bone density and bone mineral density, and the dramatic impact this drug is having on their lives. Results from the phase III trials remain on schedule to read out near the close of the year, which for us means December or January. As we head into the final analyses, our confidence holds in the mAb's mechanism of action, its capacity to build more bone in the spots that require added strength, which ought to lower fractures. Should it succeed, this will yield a transformational therapy for pediatric and adult patients living with osteogenesis imperfecta. When it comes to our currently approved products, our worldwide commercial team keeps generating meaningful revenue and cash flow annually. This year, they remain on track to produce total revenue ranging from $640 million to $670 million, representing 14%-20% growth versus last year. Crysvita is the biggest product in the portfolio, and we anticipate revenue will keep rising in the U.S., Canada, Latin America, and Turkey as an increasing number of patients start on this important medicine. On top of that, DOJOLVI, EVKEEZA, and MEPSEVII add a meaningful amount to our financial foundation, giving us revenue that comes in steadily from a range of sources and is likewise anticipated to expand as time goes on. At this point I'll hand things over to Eric Harris so he can walk through more of what his team accomplished during the prior quarter.
Appreciate that, Emil, and hello to everyone this afternoon. Like Emil said, the commercial side of our business keeps rolling out four products successfully worldwide. To begin with Crysvita down in Latin America: during the third quarter, the team produced an additional 50 start forms, which translated into roughly 50 additional patients receiving reimbursed therapy. At this point we have about 875 patients taking commercial product in that region, since the team keeps up with rising demand for this vital product. Healthcare providers regularly tell us how much better their patients feel while taking Crysvita, and that has caused more and more physicians to write prescriptions for multiple patients. Now I'll move over to Crysvita in the U.S. and Canada, where our partner Kyowa Kirin has handled commercialization from the April 2023 transition onward. Although royalty revenue for the third quarter of 2025 took a hit from the seasonality we anticipated, we also recognize that underlying growth in new start forms and new patients on reimbursed therapy has carried on. We anticipate robust revenue growth in the fourth quarter, in line with earlier quarters. Turning next to DOJOLVI in the U.S.: growth in new start forms kept climbing steadily during the third quarter, matching the patterns from prior quarters. From the 2020 launch of this product through now, the team has produced about 700 new start forms, which brought roughly 625 patients onto reimbursed therapy. Pediatric versus adult patients remains split at about 65% pediatric and 35% adult. New prescriber counts keep rising too, reaching a total of roughly 275 unique prescribers by the close of the third quarter. Regarding DOJOLVI throughout EMEA, we are nearing 300 patients treated via named patient sales in the region. We remain pleased with that demand, particularly given that we aren't actively marketing the therapy and are merely answering named patient requests. France accounts for most of the demand, yet we're also seeing growing interest among patients and families in other EMEA nations, such as Kuwait, Saudi Arabia, and Greece. To wrap up, a few quick remarks about EVKEEZA, which we started commercializing in our non-U.S. territories with formal reimbursement approvals only within the last couple of years. Across EMEA, patients on reimbursed therapy now come from nearly every major country, and we've added roughly 120 patients since the year began. All told, about 310 patients spread across 17 countries are on EVKEEZA. I'd like to acknowledge the relentless work of my European team as they keep successfully working through pricing negotiations country by country and answering named patient treatment requests throughout EMEA. As I've noted on earlier earnings calls, we still anticipate a certain amount of quarter-to-quarter revenue variability, yet our confidence in the rising underlying demand for every one of our products globally hasn't wavered. Having said that, I'll now hand things over to Howard so he can walk us through additional specifics regarding our financial results and guidance.
Thanks, Eric, and good afternoon, everyone. Before I take you through our financial results and guidance, I want to talk about the financing we announced earlier today. More details are available in the press release and the 8-K, but the main takeaway is that we raised $400 million by selling an additional 25% of our royalty interest on future Crysvita sales in the United States and Canada. Payments to OMERS start in January 2028 and are subject to a cap, just like our previous royalty financing deal with OMERS. Having many financing alternatives at our disposal was a genuine benefit, and monetizing another portion of our Crysvita royalty with OMERS proved to be the best option; we conducted a competitive process, and OMERS came through with an attractive cost of capital as well as a favorable payment holiday within a capped structure. Those terms let us minimize the impact on our P&L while maximizing liquidity. It's worth noting that Crysvita has proven to be a unique and highly valuable asset, and we expect it to continue generating significant value once the cap under this deal is hit and the royalty stream returns to Ultragenyx. With an additional $400 million on our balance sheet, we're in a stronger position to execute our planned launches, preparing us for the next stage of growth and keeping us on track toward profitability in 2027; we'll also remain committed to our financial discipline, leveraging our existing infrastructure to launch UX111 and DTX401 if they receive approval, and over the next year we'll stay focused on delivering phase III results for UX143 and GTX-102; turning now to the quarter's financials, I'll start with total revenue. For the third quarter of 2025, we reported $160 million, representing 15% growth over the third quarter of 2024. And 18% growth across the first nine months of 2025 compared with the same period in 2024. Crysvita contributed $112 million in the third quarter, made up of $57 million from North America, $47 million from Latin America and Turkey, and $8 million from Europe. DOJOLVI contributed $24 million, consistent with the steady growth trajectory we expected. EVKEEZA contributed $17 million as demand continues to rise following launch in our territories outside the United States. And MEPSEVII contributed $7 million as we continue treating patients in this ultra-rare indication. Total operating expenses for the quarter reached $331 million, including R&D of $216 million, investments in pre-launch inventory manufacturing expenses of $87 million, and cost of sales of $28 million. Operating expenses also included noncash stock-based compensation of $37 million. The net loss was $180 million, or $1.81 per share. At the close of September 30, our cash, cash equivalents, and securities stood at $447 million, and the $400 million brought in from the Crysvita royalty transaction we announced today has strengthened that position even more. Net cash used in operations came to $91 million for the three months that ended September 30, 2025, while across the nine months that ended September 30, 2025, the total reached $366 million. Operating expenses also included noncash stock-based compensation of $37 million. Looking at 2025, we expect net cash used in operations to exceed what we saw in 2024, and we're reiterating our pledge to hit full year GAAP profitability in 2027. Now to our 2025 revenue guidance, which we're reaffirming as previously given. We expect total revenue between $640 million and $670 million, which represents growth of 14% — 20% versus 2024. On Crysvita, we anticipate revenue of $460 million to $480 million, spanning all regions and every form of Crysvita revenue to Ultragenyx; that range represents 12% — 17% growth versus 2024. For DOJOLVI, we expect revenue of $100 million, representing growth of 2% — 14% versus 2024. With that, I'll pass the call to Eric Crombez, who'll provide follow-up updates on the clinical programs.
Thanks, Howard, and hello everyone this afternoon. I'll discuss UX111, which is being developed to treat MPS IIIA, and DTX401, which targets glycogen storage disease type 1A. Turning first to UX111: since we got a complete response letter in July, our interactions with the FDA — both formal and informal — have been productive. We've also gone through the extra longer-term data the FDA asked for, and what we keep observing is a durable treatment effect across multiple biomarkers tied to MPS IIIA, along with growing separation and several clinical endpoints versus natural history, while the safety profile remains acceptable. Given how those FDA conversations have gone and the internal strides we've made toward addressing the observation, we feel confident about resubmitting a BLA in early 2026, with an FDA review afterward of as long as six months. Moving to DTX401: in September, at the International Congress of Inborn Errors of Metabolism held in Japan, we shared final 96-week findings from the pivotal Glucogene study. Those findings demonstrated improvement that was durable, clinically meaningful, and statistically significant when it came to corn starch reduction, and glucose control stayed good throughout. By week 96, patients who'd been on DTX401 from the start had spent close to two years in the study, while those initially assigned to placebo had accumulated 48 weeks of DTX401 treatment following crossover to the study drug. At week 96, across both the DTX401 arm and the placebo-to-DTX401 crossover arm, daily corn starch intake fell by 61%; this also matched a mean drop in the count of daily corn doses of corn starch, with the DTX401 arm cutting nearly two doses by week 96. For the placebo-to-DTX401 crossover arm, the average decline reached 1.6 daily doses by week 96. Better glucose control and less reliance on corn starch matter especially during the overnight period, when hypoglycemia risk rises because patients are asleep and less capable of noticing symptoms. Cutting overnight corn starch doses also eases the burden of having to wait before taking corn starch and the genuine danger of doses being missed. At week 96, 67% of patients managed to eliminate no fewer than one nighttime corn starch dose. In the DTX401 arm, nighttime corn starch dropped 70% relative to baseline, and the crossover arm showed a comparable mean reduction of 75% relative to week 48. Supporting these clinical findings were gains in how patients perceived their disease, captured through a global impression of change scale, or PGIC, plus patient interviews; among the DTX401 arm, 10 of 12 patients, or 83%, reported improved disease management 96 weeks after receiving DTX401. In the placebo-to-DTX401 crossover arm, 18 of 19 patients, or 95%, saw better disease management a mere 48 weeks after receiving DTX401. Most importantly, patients could lessen their dependence on corn starch during both day and night, and they felt better in the process, all while glycemic control stayed good. For these patients, we think this may represent a therapy that changes lives and is truly transformative. During August, the FDA gave us permission to start submitting our BLA on a rolling basis, and that process is currently moving forward well. Within the finished application, we will include the clinical data from 96 weeks along with CMC updates currently being worked on, reflecting the feedback on UX111. The DTX401 rolling submission should be finished by us next month. At this point, I'll hand the call back over to Emil for a few closing words.
Thanks for that, Eric. As we get close to wrapping up the year, let me quickly walk through where we stand on milestones and catalysts. On the UX143 front for osteogenesis imperfecta, the last participants in both Orbit and Cosmic have now finished their final visits, and we're still on track to share top-line results from those trials in either December or January. Turning to GTX-102 for Angelman syndrome, we're continuing to dose patients in the 48-week Aspire study, while the supportive Aurora trial is still recruiting. As for DTX401 in GSD1A, our rolling BLA submission keeps progressing, and we anticipate completing that filing sometime in December. Turning to UX111 for Sanfilippo syndrome, we're working through the points raised in the CRL, and we expect to file the BLA again in early 2026. Our position is strong when it comes to bringing transformative treatments to people living with rare diseases, and at the same time creating substantial value for shareholders over the long term; global revenue keeps expanding, our balance sheet is solid, and we remain focused on executing against our most important priorities. We're eager to share the top-line data and report out the phase III results for GTX-102 during the back half of 2026. With that said, let's open things up for your questions, operator. Please give the Q&A instructions.
Thanks for answering me. I'm aware that you've got a highly significant data update regarding Orbit and Cosmic. According to what you mentioned, it should land near the close of 2025. Could you perhaps explain the reasoning behind that timing? Given how near it falls to the holidays, should we in fact be leaning toward expecting it at JP Morgan? Also, once the data is shared, my assumption is that it will cover both Cosmic and Orbit. Beyond that, could you address the various scenarios and how you'd elevate things to the next stage?
Fantastic. To begin, let me confirm that Cosmic and Orbit are both part of this. They'll be released simultaneously. The reason we're pointing to December or January is that we're still completing the cleaning work and finalizing the locked database analysis, so an exact date isn't available. That's why we're allowing for some flexibility — the timeline hasn't been firmly set — but our expectation is to present findings on both, whether that happens in December or January. Alright. On to the following question.
Hello, and thank you for letting me ask. I'd like to build on what Gena asked regarding OI. To begin, could you share your observations from the open label extension of the phase II? You gave us some anecdotal color, but could you offer a more quantitative view? Also, anything further on how we ought to frame the range of effect sizes for fracture reduction, and what would be required to succeed in the final analysis?
All right. We have not released an additional cut of the phase II data, so additional quantitation isn't possible from me. What we've been seeing in the trial matches what we released previously, and we chose to concentrate our efforts on the phase III. Therefore no further quantitative data exists, yet we are at ease that the phase II results you've seen hold as we progress; now, regarding our expectations for phase III, we've stated that a reduction of fracture anywhere from 40% to 70% within that band represents a very good level of fracture reduction, and I don't believe the precise percentage inside that band matters as much as how patients feel and how they function. And from the phase II study, it's quite evident that the manner in which patients function matters a great deal when it comes to their capacity to take on exercises, to walk better, get out of wheelchairs, or using walkers, and so on. So we think anywhere in that band, and I think most KOLs have proposed something better than 40%. We've seen 67% in the phase II study. I think anywhere in that band is, I think, would be a clinically meaningful change for these patients. But the impact on their overall function, I think, will in the end be even more important in how the product launches, and I would connect that back to XLH because in XLH, the RICA score change didn't really alter people's views. It shows the drug worked, but it's how patients felt on the drug that drove the adoption of that drug.
What we're saying there, then, comes out of what we've been through ourselves regarding our expectations. Yet all the data from phase II indicates this drug could be transformative — not just in altering the fracture rate, but also in the way patients feel and in how they manage daily life.
Hello, and thanks so much. Could you please just make things clear regarding UX111 and the 401 submission? My understanding was that the plan involved resolving the CMC-related questions on UX111 first, then getting that filed, and afterward handling 401. Yet at this point it appears you'll do 401 first and then 111, and you said something about an observation. Perhaps that explains it, but is there some other reason, please? Thank you.
The submissions were always quite near one another — always inside a month apart, I'd say. Certain parts of the program involving the spectrum facility have to be shared by both. A few items were particular to 111. During our Type A meeting, the FDA granted certain accommodations, though it still required us to have complete reports. A number of those reports needed a bit more time, which explains why 111 is now coming after 401. Nothing truly shifted; it was simply a matter of precisely when the final reports for the things each one needs could be assembled. 401 lacks some of those items since it's a new filing; we believed we could finish the shared items in time and keep 401 positioned to file next month. It's a minor adjustment, but I wouldn't call it a fundamental one. It comes down to what we must complete and the timing of it.
All right, and I’d like to ask just one more thing. Regarding that initial OMERS deal from 2022, I’m curious how much of it is — how near are you to that $145 million limit? Could you speak to that part?
I’ll have Howard walk us through it. Back then, we divested 30% and there was a ceiling in place. At present, we’re parting with a small amount as an expansion of that, along with an additional portion. In the end, that ceiling will encompass both of those components. Howard, perhaps you could break it down in a straightforward way for them.
Yes. Yigal, I appreciate you asking that. The truth is, we aren't in a position to share where we stand relative to the cap. That said, I believe the point Emil made matters: the earlier arrangement with OMERS — that 2020 deal involving the 30% — carries a cap of its own. When that limit is reached, the amount then moves into this new arrangement. Combined, that portion along with the extra 25 we announced today will share a separate cap equal to 1.55 times the $400 million we brought in. There happens to be a genuinely useful page in our corporate deck, available either on our website or coming to it shortly, that lays all of this out.
Hey there, good evening, and I appreciate you taking my questions. Staying with the OMERS subject, that $400 million figure you shared today — how much does it actually help with any worries investors may have regarding possible financing requirements arising in 2026, particularly in connection with September, when renewal of your priority vouchers would be necessary? If you could shed some light on that, that would be great. Then, second, regarding the Orbit and Cosmic scenarios, how are you approaching it if one study comes back positive while the other does not? For instance, suppose Orbit is positive and Cosmic is not, or the reverse. What effect do you believe that would have on your odds of securing approval in OI? Thank you.
All right, so I'll start with Orbit and Cosmic, and then I'll hand it over to Howard for the OMERS transaction, PRV, and cash runway — sorry about that. As for Orbit and Cosmic, our belief is that there's sufficient power in each trial for them to come out successful. So we anticipate success in both. In the unlikely scenario where one fails and the other succeeds, I believe the data we'd have would be adequate to back the entire span of the indication. Keep in mind that Orbit uses a placebo comparator and enrolls older children, whereas Cosmic involves younger children and uses the control. Should we demonstrate solid bone mineral density gains among the younger kids — though perhaps with P-values against bisphosphonates, say — yet still show the effect is taking place, I think we can handle that when it comes to securing the age indication, by demonstrating that a treatment effect is happening and that safety looks good at the younger ages. Cosmic is smaller, but a plus is that its population is narrower, since it enrolls only young patients aged 2 to 7 instead of also including adults; thus, despite being smaller, it's also a narrower population. So it too might succeed with that narrower population — perhaps there's less variability. It could turn out positive and demonstrate a solid effect if Orbit ended up having excessive variability and came up slightly short; but then we could show that older patients are experiencing the same effect we observed previously. So I think that if either study comes out positive, we'll be able to move forward on resolving the age range and indication question. I don't anticipate any difference in how the drug behaves. My expectation is that both studies ought to demonstrate a substantial bone mineral density benefit and improvement, and ought to show fracture improvement as well. So we have confidence in the program, and I think we can make it work. With either combination of results. Now I'll hand it to Howard for the OMERS deal and the cash runway question.
Okay, so perhaps I should frame this around how we get to profitability in 2027. A number of assumptions feed into that. To start with, the shifts in timing that happened recently are all baked into what I'm about to tell you. On the revenue side, we're expecting ongoing double-digit growth from the products we have now, plus some contribution from launches. When it comes to expenses, we'll keep managing them, though we will fold in certain chosen investments to get the most out of our launches, as we discussed today, including building pre-launch inventory. Then on the financial front, we do include monetization of three PRVs — that's UX111, DTX401, and UX143. As we've mentioned before, if one of those were not to happen, we believe the combined value of the remaining ones would still bring us to the same cash point. And naturally, the financing we announced today strengthens the balance sheet. But taken together, we believe every one of those levers will place us on our path to profitability in 2027.
Thanks a lot for fielding my question. Given what you've heard from KOLs, how are physicians weighing the idea of starting Setrusumab — say, favoring younger individuals over those whose disease has progressed further? A few checks we ran pointed toward earlier treatment in younger people, though I'd love to hear your perspective and what the community is telling you. Thanks.
If we're able to show a robust fracture benefit across the different age groups, my sense is that the first patients to be adopted will most likely be those whose disease is most severe. For a lot of people, that means the Type III and Type IV patients. We would anticipate that a larger share of those individuals receive treatment. And plenty of them are hit at a younger age. Yet truly, regardless of age, Type IIIs and IVs carry a phenotype that's more severe. Among the Type I group, you can see a spectrum of presentations. A meaningful slice — perhaps 50% or greater — experience enough fractures that it becomes a genuine burden, and for them, even without new fractures, shifts in how they behave, steering clear of activities or living sedentarily, pose a problem that makes them still want treatment. So the group where I believe most KOLs have questions is the milder Type I patients. Still, many of those individuals aren't even diagnosed very early; we do believe treatment could move to younger ages. That said, based on what we've seen with Crysvita, use among adults keeps expanding, since even in OI there are meaningful effects; they might fracture less, yet they continue to have bone dysfunction that undermines their capacity to enjoy life fully. So my expectation is use across the spectrum, though I'd anticipate younger and more severe patients gaining more immediate access than the rest.
Thanks.
Excellent. We appreciate you fielding our questions, and congratulations to the team for what was accomplished during the quarter. I have 2 quick items. The first concerns R&D. Howard, my apologies, but I believe your comments came through somewhat unevenly for listeners on the line near the start of the call. I was hoping you might go into a bit more detail regarding third quarter R&D, and you mentioned certain pre-launch manufacturing spend in that context. What's the right way for us to consider that during the quarter, and then the trajectory going forward for R&D? And then just briefly on osteogenesis imperfecta, I was curious how you folks are viewing the commercial opportunity there relative to perhaps XLH and your pre-launch efforts and, I suppose, your assessment of that market.
All right. Thank you. I'll address the commercial side, pardon me, if that works. Actually, Howard, perhaps you could handle the R&D first?
Yes, Jack, that's right. What I was trying to get across is that during the quarter, R&D expense of $216 million rose somewhat. I suppose it broke from the pattern we'd been seeing, and I wanted to clarify that this stemmed from spending on pre-launch inventory and preparations for those launches. That's what I was aiming to highlight. And I'm sorry if the line was unclear. Emil, I'll hand it to you regarding OI.
Yeah. So regarding OI — when we consider the patient population there, our perspective is that it's likely 50%-100% bigger than XLH, which comes from what we've heard talking with KOLs who treat many patients and therefore have a substantial sample size. Pricing, in our thinking, would be roughly comparable to what we have with our Crysvita program. That's what we'd anticipate. So the opportunity in OI is bigger than what we have with our XLH program. All right.
Thank you. That's a great question. Naturally, plenty of uncertainty remains about how things will ultimately unfold. As we see it today, our ASO is the strongest option and has demonstrated the most compelling long-term results. Ultimately, I believe the evidence will make it clear to parents what matters when they're weighing their choices. We've definitely spoken with many parents and we get where they're coming from regarding their children. What I'd tell you is that nobody cares whether it's the primary endpoint, a secondary one, or some other measure. What they care about is how their kids are doing, and that's bigger than any single item; we'll have every endpoint available, and I think the endpoints spanning the various programs are wide enough and overlap enough in the same domains that parents will be able to figure it out. As for the dosing schedule, I believe both programs over the long run — at minimum the Ionis program and ours — will both land in a Q3-type schedule eventually. I think it'll come down more to. I don't believe the schedule on its own will be a deciding factor, nor whether there's a loading dose or not. I don't see that really changing things. Potency will matter more. Another factor I think will be significant is our patient support programs and the way we assist patients with treatments and alternatives. We have, in my view, one of the strongest support programs anywhere, making sure people can obtain the drug and keep that access even through insurance changes and similar situations. So we'll assist patients in reaching their access objectives and getting treated; ultimately, I think potency and safety are what count. That will be the single most important factor. But when multiple products are on the market, how we manage administration and support for our patients will heavily influence what succeeds. And one final point I'd make: we are advancing our phase III and progressing very rapidly, and I believe we have the potential to get ahead of other ASOs. Still, let's find out which one is best, and my guess is patients will choose the best one once the trial is complete.
Great, thank you very much.
Thanks. Regarding the Aurora trial, our expectation is that enrollment will move along at a good pace. Quite a few patients are already waiting in line for it. No specific enrollment timeline has been established by us, but the rate at which patients signed up for a sham-controlled study struck us as impressive. This particular trial is open label. My sense is that there will be competition to get into the study. As a result, we anticipate it will proceed rather swiftly. That said, I believe this will be a significant study for expanding what we know about both the safety and the efficacy of treatment across a broader range of genotypes. So yes, we do expect it to move fast, but as of now no timeline has been fixed specifically for it.
Sure. So here's my own take, a bit more personal: I believe bisphosphonates are headed for obsolescence. In my view, they don't build good bone. What they do is preserve the bone density that's already there. The anti-sclerostin strategy, on the other hand, allows for normal bone metabolism, bone formation, and bone resorption — but in a better-balanced way. And over time, I don't think the paradigm of building bone with an anti-sclerostin and then trapping or locking it in with bisphosphonates — the approach that's become standard in the osteoporosis field — will prove to be the correct solution for OI. We currently have patients who've been on treatment for a couple of years, and we're confident that chronic therapy is genuinely required to sustain the bone gains they've made and to keep that bone healthy. I think even the FDA has its own worries regarding bisphosphonates, since long-term use of bisphosphonates appears to lead to more fractures or issues as a result of the altered structure. So we're attempting to break through that paradigm of one year of anti-sclerostin followed by bisphosphonate lock-in. That model, in my view, belongs to a different disease state and a different time; and everything we're observing tells us this is a chronic treatment. And by continuing anti-sclerostin treatment, what you're essentially doing is turning up the balance between bone production and bone resorption to the right level in a disease that normally pushes that dial down toward resorption and away from bone production. And that dial has to stay where it needs to stay so patients maintain a steady state of high-quality bone — without resorting to a bone poison to stop bone breakdown as a strategy.
From where I stand, Setrusumab represents what comes next, and for OI, bisphosphonates ought to be on their way out.
As far as I know, none were made. Eric — Crombez, I’m not sure whether you had anything you wanted to add. My sense is that there weren’t any. I’m not aware of any changes whatsoever.
No, no. Our statistical strategy is still what we're going with. We did use the chance to genuinely check the assumptions we'd made and check that statistical strategy. And everything we modeled and redid truly showed us that the strategy already in place is the correct one, and it's really giving us considerable confidence as we head toward the final data readout. Thank you very much.
Hello, and good afternoon; thank you for letting us ask something. Mehdi here, filling in for June. Building on earlier questions regarding OI, since the Cosmic superiority trials involved a younger, narrower patient group, what might happen if it fails, and what if Orbit succeeds? How would either outcome affect uptake of the drug?
Yes. Well, regarding the trial — thank you. The key thing here is that Cosmic goes head-to-head with bisphosphonates and must demonstrate superiority. To begin with, my understanding is those patients weren't on bisphosphonates. They had been receiving bisphosphonates prior to enrollment, meaning we're switching them over to our drug. The benefit from bisphosphonates, in my view, comes in at only roughly 20%, which is fairly modest, so this really doesn't worry us. That said, the concern is: suppose the trial, being on the smaller side, fails for some reason. What then? We would still possess safety and bone density findings from that group, and those, I believe, would support a label covering that age group, even without showing superiority over bisphosphonates. In particular, keep in mind that here in the U.S., proving superiority to a different therapy isn't needed to gain approval. As for the treatment that could influence uptake — honestly, I don't expect it would. People, I believe, will observe what's going on. The youngest patients, I think, face awful bone density issues. And taking in the broader picture spanning the age group, I believe, will encourage uptake across every age group. So I'm grateful for the question, though I do believe that at this point, the effect either way won't be significant.
Thanks.
I'll kick things off, and then I'll hand it over to Howard. What I'd say is that we're continuously seeking the cheapest possible funding; and here, the value that people assigned to the Crysvita royalty was outstanding, so we came out ahead on that. That said, my sense is that ordinarily, we'd prefer to hold onto our revenue streams rather than do something like this. Still, I think we've simply reached this pivotal point right now. From our standpoint, though, with 3, and possibly 4, products hitting the market over the coming 2 years, we're going to find ourselves in a drastically different position before long, and this won't be a topic we need to discuss; but perhaps, Howard, you could walk through how the Crysvita deal came together.
Right. We looked at quite a few options. In the end, this was a competitive situation, and we were searching. Our aim was to secure substantial proceeds while keeping our cost of capital as low as possible, so the interest expense hit to the P&L would be minimal, and at the same time we wanted to preserve as much cash as we could. The payment holiday supports that goal, and these other terms do too. But like Emil said, we believed we could bring some revenues scheduled for later forward into the present, which would strengthen our balance sheet so we'd have everything required to get as many as four programs launched soon and set us on the growth trajectory we anticipate. Great. Thanks.
Right. Thanks. I'll say a few words on that, and Eric, I'm not sure whether we should tack on anything further, but my thinking is this: if you're able to pull off a gene therapy, what you're after is a meaningful impact across most of the people you treat, correct? You want the results to be persuasive. So at present, we're raising the dose in an effort to boost the share of patients who experience that type of response; the things we're observing have us enthusiastic, and some findings will be shared before long. That said, Eric, perhaps you could describe which elements of the Wilson data you'd want to see as we reach that call on moving into phase three.
Right, no. The key thing to emphasize is that above all, our goal is getting most patients off the existing standard of care, meaning chelators plus zinc. Emil brought up raising the dose. On top of that, we're revising our immunomodulation regimen; in our view those adjustments should at minimum add to, and perhaps work synergistically with, boosting or truly maximizing how well this gene therapy performs. The data we've shared publicly so far are strong, and we came near that target. We felt it justified spending this additional time running this cohort in an effort to get the majority of patients off treatment. What's helpful with Wilson and when you're tracking copper is that there are many distinct approaches to measuring it. My sense is we'll be in a position to reach a definitive decision on that. All right. Thanks. That, I believe, is what I wanted to ask.
Thank you. Our perspective has consistently been that the entire exclusivity picture matters a great deal. Naturally, we hold orphan designation, and that grants us a particular form of protection that extends well beyond 2030 — so that's where I'd begin. That covers the initial piece. Then, secondly, absent any patents at all, the reality is that biologics of this kind seldom undergo change. Subsequent biologics might emerge, yet my view is that the situation would not resemble a standard exclusivity loss. Covering every patent detail currently shielding this program isn't something I'm able to do. On top of that, there are further items we're assembling tied to what we've discovered about treating patients, about delivering chronic therapy, and about other essential matters. As things stand, our comfort level with the current position remains fairly high. Setrusumab, though, has existed for some time, and previously it was in development for OI — that is, osteoporosis. Still, my sense is that combining orphan drug exclusivity with the intellectual property we anticipate having ought to leave us well positioned to advance this program.
Hello there. Nice work on the advancement, and I appreciate you answering my questions. I wanted to know if you might take us through the rescue arm in Orbit once more, and explain how it gets incorporated into the statistical analysis plan. Then, given your discussions with neurologists, what is their perspective on the value of Bayley-4 cognition as opposed to Bayley-4 communication? Thanks.
Regarding the rescue arm, its purpose is that when a patient experienced many fractures and plenty of PIs grew concerned — since they often enter the trial already on bisphosphonates, with numerous fractures — they would essentially be trapped in the trial and would need to drop out if the child deteriorated. So we would give them the option to rescue should they have a substantial number of fractures, upon observing a specific count of fractures. However, they must remain in the trial for a minimum of one year. Following that, rescue would become available. The concept is that given a one-year sample time plus a greater fracture count, sufficient time will have passed to evaluate their AFR — that is, to establish their annualized fracture rate. When fractures are numerous, a one-year timeframe suffices to serve as the AFR estimate. Thus, should a patient enter the rescue arm, we count all the time they spent on drug within their analysis and derive their AFR from the sampling time. Is that clear to you? Since we are calculating an annualized fracture rate reduction, we simply require a sample time that adequately estimates their true fractures. That is how it operates; yet it was inherently necessary for running the trial, purely because physicians could not leave patients off bisphosphonates forever and face an enormous number of problems; and instead of letting them withdraw, keeping them enrolled and crossing them over would be preferable. So I appreciate that question. The following question concerned the utility of Bayley-4 versus cognition versus communication. Honestly speaking, the primary endpoint is irrelevant, because I have never spoken with parents who ask me what a trial's primary endpoint is. You may discuss what you are measuring, but they will never rely on primary or secondary when making decisions. They wish to see the entire story. And that entire story is what we will deliver. Our program will include receptive and expressive communication. We will have answers for that, and we compare them; and which one you position first is more a matter of regulatory strategy. In my view, it holds limited value, at least in rare. I am aware that in other large-market diseases, the primary endpoint and its precise design become hugely important. But in rare, I have not witnessed that. Honestly, that hasn't been a big deal, since everyone reviews the full dataset and factors it in. So our approach is to zero in on the Bayley-4 condition. That's where we observed the strongest signal. It's an issue with a core brain function. That said, we're also examining the remaining communication measures and other endpoints — both via the multi-domain responder index and via each of the individual secondary and tertiary endpoints. As a result, we'll be in a position to address every one of those issues, every endpoint, and also to offer comparisons across the products; so that, I believe, explains why I'm not too worried about which one people picked as primary. For regulatory reasons, that choice is necessary. Yet in everyday life. Never once did I walk into my doctor's office and say, "My primary endpoint is this one, while my secondary is that one, so what can you do for me?" Nobody talks like that; therefore I'm quite at ease with what we've got. We're hitting all the domains. And I'd say I feel positive about the sort of data we've observed thus far in the patients enrolled in our expansion study. It gives me confidence that we'll observe the sorts of shifts in communication and cognition and sleep and behaviors and fine motor and expressive that will be, in my view, a wonderful future for Angelman patients, honestly, since who would have imagined we could alter a child with severe developmental delay and genuinely begin making their brains develop? To me it's a miraculous situation; being part of it makes us truly proud.
Great. Appreciate all the color.
Hey, guys. Thanks for taking the question. I just wanted to ask about the Aspire Angelman study that's ongoing — can you say anything about the variability you're observing, anything from the blinded data, any baseline characteristics, really anything at all that gives you confidence in the study as it continues? Thanks. Things are progressing nicely with this trial, and our confidence is high; it's simply not our practice to discuss trial data while a study remains active. Eric, I'm not sure whether you could offer any big-picture perspective regarding the patient population. My understanding is that they closely resemble the expansion patients about whom we've already shared results.
Yeah. No, exactly. That matters quite a bit, in my view. Before anything moves into phase III, we make sure it has already been tested, and we deliberately transfer what we learned and understood during phase 2. That means the criteria for entering the trial stay the same, the endpoints stay the same, and the patient group stays the same. Once more, in Aspire we're focusing on individuals who carry the full deletion. These are people who essentially produce no protein at all, show a highly uniform disease presentation, and sit at the most severe edge of that range. Because of that, we expect the findings to line up very closely with what phase 2 showed us.
Great. Thanks.
Thank you. That brings today's call to a close. Should you have any further questions, feel free to reach out by phone or at ir@ultragenyx.com. We appreciate you being with us.
Thank you. All parties may now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Ultragenyx Pharmaceutical Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Ultragenyx Pharmaceutical Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.